CryoLife Promotes D. Ashley Lee to Executive Vice President
November 03 2004 - 8:30AM
PR Newswire (US)
CryoLife Promotes D. Ashley Lee to Executive Vice President
ATLANTA, Nov. 3 /PRNewswire-FirstCall/ -- CryoLife, Inc.
(NYSE:CRY), a biomaterials and biosurgical device company, reported
today that it has promoted D. Ashley Lee, 40, from Vice President
Finance, Treasurer and Chief Financial Officer to Executive Vice
President, Treasurer and Chief Financial Officer. In this newly
created position, he will be responsible for all financial
operations, purchasing, human resources, corporate communications,
information technology and Wall Street relations for the Company.
He will continue to report directly to Steven G. Anderson,
CryoLife's President, Chief Executive Officer and founder. Mr. Lee,
a University of Mississippi graduate, joined the Company as
Controller in 1994, and was subsequently promoted to Vice President
and Chief Financial Officer of the Company in April of 2000. Mr.
Lee was an Audit Manager with Ernst and Young for seven years from
1987 to 1993. Prior to joining CryoLife, Ashley was Director of
Finance at Compass Retail, a wholly- owned subsidiary of Equitable
Real Estate. Steven G. Anderson, President and Chief Executive
Officer, stated, "I'm delighted to announce Ashley's promotion to
Executive Vice President as it reflects the tremendous
contributions that he has made to the Company and the leadership he
has demonstrated. The Board joins with me to offer congratulations
and best wishes to Ashley for his continuing efforts on behalf of
CryoLife's success." Founded in 1984, CryoLife, Inc. is a leader in
the processing and distribution of implantable living human tissues
for use in cardiovascular and vascular surgeries throughout the
United States and Canada. The Company's BioGlue(R) Surgical
Adhesive is FDA approved as an adjunct to sutures and staples for
use in adult patients in open surgical repair of large vessels and
is CE marked in the European Community and approved in Canada for
use in soft tissue repair and approved in Australia for use in
vascular and pulmonary sealing and repair. The Company also
manufactures the SG Model #100 vascular graft, which is CE marked
for distribution within the European Community. For additional
information about the company, visit CryoLife's web site:
http://www.cryolife.com/ Contact: Joseph T. Schepers Vice
President, Corporate Communications (770) 419-3355 DATASOURCE:
CryoLife, Inc. CONTACT: Joseph T. Schepers, Vice President,
Corporate Communications of CryoLife, Inc., +1-770-419-3355 Web
site: http://www.cryolife.com/
Copyright
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jun 2024 to Jul 2024
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jul 2023 to Jul 2024